Enzalutamide Now FDA-Approved for the Treatment of Metastatic Castration-Sensitive Prostate Cancer

XTANDI® enzalutamide approved for the treatment of patients with metastatic castration-sensitive prostate cancer mCSPC based on results of the ARCHES trial, XTANDI is now the first and only oral treatment approved by the FDA in three distinct types of advanced prostate cancer.

Read the full article here

Related Articles